JP2020040969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020040969A5 JP2020040969A5 JP2019209416A JP2019209416A JP2020040969A5 JP 2020040969 A5 JP2020040969 A5 JP 2020040969A5 JP 2019209416 A JP2019209416 A JP 2019209416A JP 2019209416 A JP2019209416 A JP 2019209416A JP 2020040969 A5 JP2020040969 A5 JP 2020040969A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- therapeutic cells
- polypeptide
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021195285A JP2022024158A (ja) | 2013-06-05 | 2021-12-01 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831428P | 2013-06-05 | 2013-06-05 | |
| US61/831,428 | 2013-06-05 | ||
| US201461949847P | 2014-03-07 | 2014-03-07 | |
| US61/949,847 | 2014-03-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018152650A Division JP6818720B6 (ja) | 2013-06-05 | 2018-08-14 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021195285A Division JP2022024158A (ja) | 2013-06-05 | 2021-12-01 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020040969A JP2020040969A (ja) | 2020-03-19 |
| JP2020040969A5 true JP2020040969A5 (enExample) | 2020-07-09 |
Family
ID=52008744
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517976A Expired - Fee Related JP6467406B2 (ja) | 2013-06-05 | 2014-06-04 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| JP2018152650A Expired - Fee Related JP6818720B6 (ja) | 2013-06-05 | 2018-08-14 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| JP2019209416A Pending JP2020040969A (ja) | 2013-06-05 | 2019-11-20 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| JP2021195285A Pending JP2022024158A (ja) | 2013-06-05 | 2021-12-01 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517976A Expired - Fee Related JP6467406B2 (ja) | 2013-06-05 | 2014-06-04 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
| JP2018152650A Expired - Fee Related JP6818720B6 (ja) | 2013-06-05 | 2018-08-14 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021195285A Pending JP2022024158A (ja) | 2013-06-05 | 2021-12-01 | カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9913882B2 (enExample) |
| EP (2) | EP3569253A1 (enExample) |
| JP (4) | JP6467406B2 (enExample) |
| AU (1) | AU2014274916B2 (enExample) |
| CA (1) | CA2912172A1 (enExample) |
| DK (1) | DK3004329T3 (enExample) |
| ES (1) | ES2791598T3 (enExample) |
| WO (1) | WO2014197638A2 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP2970372B1 (en) | 2013-03-15 | 2020-09-30 | Celgene Corporation | Modified t lymphocytes |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| EP3104866A4 (en) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| PT3575315T (pt) * | 2014-09-15 | 2022-12-16 | Agc Biologics S P A | Recetores de antigénios quiméricos |
| AU2015330898B2 (en) | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| WO2016071758A1 (en) | 2014-11-03 | 2016-05-12 | Leiden University Medical Center | T cell receptors directed against bob1 and uses thereof |
| EP3234145B1 (en) * | 2014-12-15 | 2019-06-05 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| WO2016100236A2 (en) * | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| RU2751362C2 (ru) | 2014-12-29 | 2021-07-13 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| GB201503133D0 (en) * | 2015-02-24 | 2015-04-08 | Ucl Business Plc And Syncona Partners Llp | Chimeric protein |
| AU2016230828B2 (en) | 2015-03-10 | 2020-10-22 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| US11091546B2 (en) * | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| WO2017040930A2 (en) | 2015-09-03 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Biomarkers predictive of cytokine release syndrome |
| CA3007473A1 (en) * | 2015-12-14 | 2017-06-22 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
| CA3009852A1 (en) | 2015-12-28 | 2017-07-06 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
| CA3019835A1 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| EP3448995A1 (en) | 2016-04-25 | 2019-03-06 | Universität Basel | Allele editing and applications thereof |
| WO2017210617A2 (en) | 2016-06-02 | 2017-12-07 | Porter, David, L. | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| WO2017207744A1 (en) * | 2016-06-03 | 2017-12-07 | Institut National De La Recherche Agronomique (Inra) | Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein |
| WO2018068022A1 (en) | 2016-10-06 | 2018-04-12 | Poseida Therapeutics, Inc. | Inducible caspases and methods for use |
| JP7467117B2 (ja) | 2016-10-07 | 2024-04-15 | ノバルティス アーゲー | 癌の治療のためのキメラ抗原受容体 |
| CN109983027A (zh) * | 2016-10-20 | 2019-07-05 | 细胞基因公司 | 基于cereblon的可异二聚化嵌合抗原受体 |
| US20190365806A1 (en) * | 2016-11-02 | 2019-12-05 | Universität Basel | Immunologically discernible cell surface variants for use in cell therapy |
| AU2018219226B2 (en) | 2017-02-07 | 2024-12-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| AU2018220843B2 (en) | 2017-02-14 | 2023-09-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of engineering human induced pluripotent stem cells to produce liver tissue |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| EP3621988A1 (en) | 2017-05-09 | 2020-03-18 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| CN107365798B (zh) * | 2017-07-13 | 2020-07-14 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用 |
| JP2020532987A (ja) | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス，インコーポレイティド | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
| CN107488636A (zh) * | 2017-09-30 | 2017-12-19 | 山东兴瑞生物科技有限公司 | 一种携带分子开关的抗her2嵌合抗原受体修饰的免疫细胞及其应用 |
| WO2019084288A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS |
| EP3703689A1 (en) | 2017-11-01 | 2020-09-09 | Allogene Therapeutics, Inc. | Modified caspase-9 polypeptides and methods of use thereof |
| AU2018378955A1 (en) | 2017-12-08 | 2020-06-18 | Bellicum Pharmaceuticals, Inc. | Methods for enhancing and maintaining CAR-T cell efficacy |
| WO2019126344A1 (en) | 2017-12-20 | 2019-06-27 | Bellicum Pharmaceuticals, Inc. | Multimeric piperidine derivatives |
| AU2018393110B2 (en) | 2017-12-20 | 2023-04-27 | Poseida Therapeutics, Inc. | VCAR compositions and methods for use |
| WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| AU2019218729B2 (en) | 2018-02-06 | 2025-12-04 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| AU2019227979B2 (en) | 2018-03-02 | 2024-09-05 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| SI3844267T1 (sl) | 2018-08-31 | 2025-10-30 | Novartis Ag | Postopki izdelave celic, ki izražajo receptorje himernega antigena |
| WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| US20220002674A1 (en) | 2018-10-31 | 2022-01-06 | Bellicum Pharmaceuticals, Inc. | T cells with suicide switch |
| IL285941B1 (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN |
| IL328846A (en) | 2019-03-01 | 2026-08-01 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors and compounds comprising them for the treatment of cancer and autoimmune diseases |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220213434A1 (en) | 2019-05-10 | 2022-07-07 | The Regents Of The University Of California | Modified pluripotent cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| JP7403241B2 (ja) * | 2019-06-07 | 2023-12-22 | 小林製薬株式会社 | 内臓脂肪の視認性向上方法 |
| WO2021007396A2 (en) * | 2019-07-09 | 2021-01-14 | The Children's Mercy Hospital | Engineered regulatory t cells |
| EP3769816A1 (en) * | 2019-07-25 | 2021-01-27 | Ospedale Pediatrico Bambino Gesù | Car-cd123 vector and uses thereof |
| BR112022003553A2 (pt) | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| EP3812465A1 (en) | 2019-10-21 | 2021-04-28 | Universität Ulm | Adenovirus comprising a modified adenovirus hexon protein |
| CN115135672A (zh) | 2019-12-20 | 2022-09-30 | 波赛达治疗公司 | 抗muc1组合物和使用方法 |
| US20210222128A1 (en) * | 2020-01-22 | 2021-07-22 | Massachusetts Institute Of Technology | Inducible tissue constructs and uses thereof |
| IL295063A (en) | 2020-02-04 | 2022-09-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Chimeric antigen receptors (car) against dinitrophenol |
| EP4104187A1 (en) | 2020-02-14 | 2022-12-21 | Novartis AG | Method of predicting response to chimeric antigen receptor therapy |
| PE20221757A1 (es) | 2020-02-24 | 2022-11-11 | Allogene Therapeutics Inc | Celulas t con car de bcma con actividades mejoradas |
| JP2023516008A (ja) | 2020-02-27 | 2023-04-17 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| KR20230107617A (ko) | 2020-11-13 | 2023-07-17 | 노파르티스 아게 | 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| CN114042030B (zh) * | 2021-11-29 | 2022-06-24 | 上海天安智谷干细胞科技集团有限公司 | 一种含有脂肪间充质干细胞冻干粉的化妆品及抗炎药物 |
| CN119584971A (zh) * | 2022-04-11 | 2025-03-07 | 密歇根大学董事会 | 肽功能的化学遗传调控 |
| EP4551240A1 (en) | 2022-07-08 | 2025-05-14 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
| CN117625544A (zh) * | 2022-08-25 | 2024-03-01 | 华中科技大学 | 基于代谢调控的改造的效应t细胞及其改造方法 |
| KR20250067174A (ko) | 2022-09-15 | 2025-05-14 | 노파르티스 아게 | 키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료 |
| CN121368427A (zh) * | 2023-03-28 | 2026-01-20 | 学校法人慈惠大学 | 非人动物、试剂盒以及置换器官的制造方法 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4514506A (en) | 1982-02-23 | 1985-04-30 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services | Method for the identification and purification of human lung tumor-associated antigens (hLTAA) and clinical detection and determination of these antigens |
| EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
| FR2610631B1 (fr) | 1987-02-09 | 1989-11-24 | Pasteur Institut | Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme |
| US5869608A (en) | 1989-03-17 | 1999-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis |
| US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
| US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
| US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| CA2067031C (en) | 1991-04-26 | 2003-02-18 | Shigekazu Nagata | Dna coding for human cell surface antigen |
| US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
| DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
| GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| HUT73101A (en) | 1993-02-12 | 1996-06-28 | Harvard College | Method for regulating transcription of targeted genes and other biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5426027A (en) | 1993-05-20 | 1995-06-20 | The Government Of The United States Of America As Represented By The Secretary | Nucleic acid probes and methods for detecting Candida DNA cells in blood |
| US5648226A (en) | 1993-07-22 | 1997-07-15 | Ludwig Institute For Cancer Research | Isolated peptides derived from tumor rejection antigens, and their use |
| WO1995004542A1 (en) | 1993-08-06 | 1995-02-16 | Cytel Corporation | Cloning and characterization of the complete mage-1 gene |
| US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
| WO1996012796A1 (en) | 1994-10-25 | 1996-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Conditional transformation of genetically engineered cells |
| US5837544A (en) | 1995-02-02 | 1998-11-17 | Cell Genesys, Inc. | Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase |
| US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6010878A (en) | 1996-05-20 | 2000-01-04 | Smithkline Beecham Corporation | Interleukin-1 β converting enzyme like apoptotic protease-6 |
| KR20000022445A (ko) | 1996-07-10 | 2000-04-25 | 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 | 수상돌기 세포의 활성화 방법 |
| US5955596A (en) | 1996-07-26 | 1999-09-21 | American Cyanamid Company | NucA protein of Haemophilus influenzae and the gene encoding that protein |
| US6046158A (en) | 1996-12-20 | 2000-04-04 | Board Of Regents The University Of Texas Systems | Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof |
| US5965242A (en) | 1997-02-19 | 1999-10-12 | Eastman Kodak Company | Glow-in-the-dark medium and method of making |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US6403765B1 (en) | 1998-06-16 | 2002-06-11 | Thomas Jefferson University | Truncated Apaf-1 and methods of use thereof |
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| WO2001048154A1 (en) | 1999-12-28 | 2001-07-05 | Toyoshima, Kumao | Maturation-promoting agent for immature dendritic cells |
| US7435585B2 (en) | 2000-01-03 | 2008-10-14 | University Of Pennsylvania | Auto-stimulating cells and methods for making and using the same |
| SE0001642D0 (sv) | 2000-05-04 | 2000-05-04 | Sahltech Ab | Reagent for detection of biomolecules, and use thereof |
| US20030232055A1 (en) | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
| US6943245B2 (en) | 2000-08-10 | 2005-09-13 | Board Of Regents, The University Of Texas System | Tumor suppressor CAR-1 |
| AU2002221780A1 (en) | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| WO2002054066A2 (en) | 2000-12-14 | 2002-07-11 | The Burnham Institute | Non-apoptotic forms of cell death and methods of modulation |
| US20020160975A1 (en) * | 2001-02-08 | 2002-10-31 | Thomas Jefferson University | Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis |
| WO2003006606A2 (en) | 2001-07-09 | 2003-01-23 | Oklahoma Medical Research Foundation | Targeted fusion proteins and methods for the characterization of cellular membrane domains |
| EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| US20030082163A1 (en) | 2001-10-26 | 2003-05-01 | Suyu Shu | Fused cells, methods of forming same, and therapies utilizing same |
| CA2516320C (en) | 2003-02-18 | 2015-05-26 | Kevin Slawin | Induced activation in dendritic cells |
| WO2007050095A2 (en) | 2004-11-19 | 2007-05-03 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| US20060263368A1 (en) * | 2005-01-10 | 2006-11-23 | Research Development Foundation | Targeted chimeric molecules for cancer therapy |
| WO2006133398A2 (en) | 2005-06-08 | 2006-12-14 | Invitrogen Corporation | In vitro activated donor t-cells to promote transplant engraftment |
| KR100705981B1 (ko) | 2005-10-12 | 2007-04-10 | 주식회사 리제론 | 인간 성장호르몬을 포함하는 탈모방지 또는 발모촉진용조성물 |
| US20080300202A1 (en) * | 2006-05-18 | 2008-12-04 | The State of Oregon acting by and through the State Board of Higher Education on behalf of the | Subtractive transgenics |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| US20120328628A1 (en) | 2006-07-07 | 2012-12-27 | The Regents Of The University Of California | Antibodies to conformationally trapped proteins |
| US8691210B2 (en) | 2006-10-19 | 2014-04-08 | David M Spencer | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| MX348010B (es) | 2007-04-07 | 2017-05-23 | Whitehead Inst Biomedical Res | Reprogramacion de celulas somaticas. |
| US9213999B2 (en) | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| EP2006376A1 (en) | 2007-06-21 | 2008-12-24 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
| US8236318B2 (en) | 2007-11-07 | 2012-08-07 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| AU2009221915A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 12 binding proteins |
| AU2009292996B2 (en) | 2008-09-22 | 2015-04-23 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters |
| WO2011035018A2 (en) | 2009-09-18 | 2011-03-24 | Fate Therapeutics, Inc. | Suicide ready cells |
| JP5975983B2 (ja) | 2010-04-16 | 2016-08-23 | ベリカム ファーマシューティカルズ， インコーポレイテッド | 固形腫瘍を処置するための方法 |
| US9089520B2 (en) * | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| EP3692794A1 (en) | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| EP3569253A1 (en) | 2013-06-05 | 2019-11-20 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| EP3114217A4 (en) | 2014-03-07 | 2017-09-20 | Bellicum Pharmaceuticals, Inc. | Caspase polypeptides having modified activity and uses thereof |
| AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
| WO2016100236A2 (en) * | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| EP3234145B1 (en) | 2014-12-15 | 2019-06-05 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
-
2014
- 2014-06-04 EP EP19173088.6A patent/EP3569253A1/en not_active Withdrawn
- 2014-06-04 CA CA2912172A patent/CA2912172A1/en active Pending
- 2014-06-04 EP EP14807405.7A patent/EP3004329B1/en active Active
- 2014-06-04 ES ES14807405T patent/ES2791598T3/es active Active
- 2014-06-04 US US14/296,404 patent/US9913882B2/en active Active
- 2014-06-04 JP JP2016517976A patent/JP6467406B2/ja not_active Expired - Fee Related
- 2014-06-04 AU AU2014274916A patent/AU2014274916B2/en active Active
- 2014-06-04 DK DK14807405.7T patent/DK3004329T3/da active
- 2014-06-04 WO PCT/US2014/040964 patent/WO2014197638A2/en not_active Ceased
-
2018
- 2018-02-05 US US15/888,948 patent/US10525110B2/en active Active
- 2018-08-14 JP JP2018152650A patent/JP6818720B6/ja not_active Expired - Fee Related
-
2019
- 2019-11-20 JP JP2019209416A patent/JP2020040969A/ja active Pending
-
2020
- 2020-01-03 US US16/734,104 patent/US11839647B2/en active Active
-
2021
- 2021-12-01 JP JP2021195285A patent/JP2022024158A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feldman | Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments | |
| US11219628B2 (en) | Replacement of cytotoxic preconditioning before cellular immunotherapy | |
| JP2019519215A5 (enExample) | ||
| JP2014169326A5 (enExample) | ||
| JP2016521709A5 (enExample) | ||
| CN108392633A (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| JP2014509841A5 (enExample) | ||
| ES2717661T3 (es) | Terapia de combinación para el tratamiento de las enfermedades autoinmunes | |
| KR20230027322A (ko) | 암-표적화된 ｉｌ-12 면역요법 | |
| CN109310746A (zh) | 过继细胞转移与溶瘤病毒组合疗法 | |
| JP2020517692A5 (enExample) | ||
| JP2018500390A5 (enExample) | ||
| JP2014500278A5 (enExample) | ||
| JP2024540275A5 (enExample) | ||
| TW202600150A (zh) | 編碼ccl21之重組棒狀病毒 | |
| JP2012100676A5 (enExample) | ||
| JP2015524413A5 (enExample) | ||
| JP2019507775A5 (enExample) | ||
| Hong et al. | substance-P prevents cardiac ischemia-reperfusion injury by modulating stem cell mobilization and causing early suppression of injury-mediated inflammation. | |
| EP4419143A1 (en) | Methods of use and administration of encapsulated cells | |
| RU2017126212A (ru) | Композиция | |
| JP2009532326A5 (enExample) | ||
| Zhang et al. | Hematopoietic stem and immune cells in chronic HIV infection | |
| TW201806970A (zh) | 嵌合抗原受體、及其利用 | |
| EP0684842B1 (fr) | Composition pour le traitement de tumeurs et l'immunisation d'organismes a l'encontre de tumeurs |